Germline mutations in the TP53 gene
- PMID: 8718514
Germline mutations in the TP53 gene
Abstract
Since the majority of germline mutations in the TP53 gene seem to occur in LFS or LFL families, and these are rare, research is best conducted in a collaborative setting (Li and Fraumeni, in press). In a report from a meeting at Bethesda in 1993, the following areas were outlined for collaborative study: the correlation (if any) of phenotypes with specific mutation; age specific penetrance; cumulative cancer incidence; gender differences in tumour development in carriers; the effects of DNA damaging agents on individuals with a TP53 mutation; the frequency of TP53 germline mutations in cohorts of patients with rare childhood tumours (eg adrenocortical carcinoma); and the psychosocial aspects of predictive TP53 testing. In addition, if, as seems likely from recent data, X irradiation in these individuals induces DNA damage that is tolerated, urgent collaborative studies are needed to investigate new methods of screening, such as magnetic resonance imaging. Treatment modalities should be carefully chosen, and for this reason alone, predictive testing may be desirable in all LFS and LFL families. Individuals carrying TP53 mutations could be offered chemoprevention within trials in an effort to reduce their mortality from cancer.
Similar articles
-
TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.J Med Genet. 2010 Jun;47(6):421-8. doi: 10.1136/jmg.2009.073429. J Med Genet. 2010. PMID: 20522432
-
Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.Cancer Res. 2003 Oct 15;63(20):6643-50. Cancer Res. 2003. PMID: 14583457
-
Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families.Cancer Res. 1997 Aug 1;57(15):3245-52. Cancer Res. 1997. PMID: 9242456
-
Germline TP53 mutations and Li-Fraumeni syndrome.Hum Mutat. 2003 Mar;21(3):313-20. doi: 10.1002/humu.10185. Hum Mutat. 2003. PMID: 12619118 Review.
-
Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome.Curr Opin Oncol. 2010 Jan;22(1):64-9. doi: 10.1097/CCO.0b013e328333bf00. Curr Opin Oncol. 2010. PMID: 19952748 Review.
Cited by
-
Routine TP53 testing for breast cancer under age 30: ready for prime time?Fam Cancer. 2012 Dec;11(4):607-13. doi: 10.1007/s10689-012-9557-z. Fam Cancer. 2012. PMID: 22851211
-
Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma.J Clin Endocrinol Metab. 2013 Jan;98(1):E119-25. doi: 10.1210/jc.2012-2198. Epub 2012 Nov 21. J Clin Endocrinol Metab. 2013. PMID: 23175693 Free PMC article.
-
Organization and running of the first comprehensive hereditary cancer clinic in India.Hered Cancer Clin Pract. 2005 Nov 15;3(4):165-70. doi: 10.1186/1897-4287-3-4-165. Hered Cancer Clin Pract. 2005. PMID: 20223043 Free PMC article.
-
Population prevalence of hereditary breast cancer phenotypes and implementation of a genetic cancer risk assessment program in southern Brazil.Genet Mol Biol. 2009 Jul;32(3):447-55. doi: 10.1590/S1415-47572009005000058. Epub 2009 Sep 1. Genet Mol Biol. 2009. PMID: 21637504 Free PMC article.
-
Two Li-Fraumeni syndrome families with novel germline p53 mutations: loss of the wild-type p53 allele in only 50% of tumours.Br J Cancer. 1998 Apr;77(7):1034-9. doi: 10.1038/bjc.1998.172. Br J Cancer. 1998. PMID: 9569035 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Molecular Biology Databases
Research Materials
Miscellaneous